Repligen Corporation [RGEN]
As of 2026-07-29 · spot $145.00 · framework v1.5.1
This document issues no position verdict. It states what a position would have to look like if the book chose to take one, and what would kill it. The book decides.
criteria.md is explicit: "Any proposed options structure requires the actual chain pulled first — open
interest and quoted size for the specific strikes and expiry."
Chain pulled 2026-07-29 via Alpaca (/v2/options/contracts for discovery, /v1beta1/options/snapshots for
quotes and Greeks). Only one listed expiry exists in the Dec-2026 → Jan-2027 window: 2026-12-18.
| Strike | Bid | Ask | Spread as % of mid | IV | Delta | Open interest |
|---|---|---|---|---|---|---|
| 130 | 26.15 | 29.64 | 12.5% | 0.547 | 0.701 | — |
| 135 | 22.45 | 26.87 | 17.9% | 0.532 | 0.662 | — |
| 140 | 20.11 | 23.89 | 17.2% | 0.528 | 0.621 | 15 |
| 145 | 17.45 | 21.46 | 20.6% | 0.521 | 0.579 | 2 |
| 150 | 15.14 | 19.01 | 22.6% | 0.514 | 0.537 | — |
| 155 | 13.63 | 16.90 | 21.4% | 0.517 | 0.497 | — |
| 160 | 11.52 | 15.18 | 27.4% | 0.512 | 0.456 | — |
| 165 | 11.10 | 12.51 | 12.0% | 0.512 | 0.418 | 1 |
| 175 | 7.12 | 10.99 | 42.7% | 0.509 | 0.346 | 12 |
| 180 | 5.50 | 9.54 | 53.7% | 0.496 | 0.307 | — |
| 190 | 4.07 | 7.66 | 61.2% | 0.501 | 0.252 | 1 |
| 200 | 3.14 | 6.19 | 65.4% | 0.510 | 0.208 | 1 |
Total open interest across the entire Dec-2026 call chain: 37 contracts, maximum 15 at any single strike.
No options structure in RGEN is investable at any size. A 15-contract maximum open interest is a $22k notional at the 140 strike. Crossing a 20–65%-of-mid spread destroys the entire edge before the thesis is tested. This is the HCA failure mode recorded in
criteria.md, reproduced exactly: "A vehicle that cannot be filled is not a vehicle."
Consequence: any RGEN expression is common stock only. No calls, no spreads, no collar, no covered write. This is not a preference; it is what the chain permits.
Equity liquidity is adequate. Nasdaq Global Select, $8.18bn market cap, 56.4m shares. IEX-feed 60-day median volume is 93,570 shares = $13.6m/day, and IEX is a small fraction of the consolidated tape, so that is a floor, not an estimate. A position of any size this book would take is exitable in a day or two.
Recorded for completeness, conditional on the book overriding a Valuation-Criteria FAIL. criteria.md:
"Cheap cannot rescue a failure" on Quality, and the Valuation Criteria is BINDING for the long-only
absolute-return strategy. Both are FAIL here.
| Vehicle | Common stock only. Forced by §1. |
| Direction | Long, if at all — the Short Mechanism Criteria does not qualify (growth accelerating, margin runway not exhausted). |
| Thesis horizon | 12 months, not 5 years. The multiple mean-reversion is the trade; the compounding case fails. |
| Entry | The Q2 print already moved the stock +11.0% (2026-07-28). Entry above ~$150 gives up most of the multiple-percentile edge. |
| Sizing | Inverse-volatility. 252-day realised vol 46.5% — roughly 2.5x a typical large-cap, so a half-to-third-size slot at best. This is the active protection while Downside Criteria remains MEASURED. |
| Target | $163 pro forma / $176 standalone (12 months). See RGEN_Valuation.md §2. |
| Invalidation | §4 below. |
Momentum Criteria (MEASURED, entry timing only): +9.0% 12-1. Mid-pack, not a timing signal in either direction. The name is 15.8% below its 52-week high and 55.3% below its 2021 high of $324.24; 6-month return is −9.4% while 3-month is +28.2% — a name that broke and has been re-rating off the low for one quarter.
Type: MEASURED. Logged and scored. It does not reject the name.
The 2025–26 bioprocessing "recovery" is a restocking cycle, not a demand step-up — and it cannot be falsified from the filings, because the order disclosure that would have shown it was retired.
The chain of evidence:
If it is restocking, growth reverts towards end-market volume growth — call it 5–7% — once safety stocks are rebuilt, and it does so without warning because there is no order metric to telegraph it.
Compounding causes, all named and all already contracted or announced:
Pro-forma revenue ~$900m × 7.33x = $6,597m EV; less ~$300m net debt = $6,297m equity ÷ 63.0m shares = $100/share.
Bear case: $100, −31.0% from $145.00. Probability 27%.
Logged to trade_recommendations.jsonl for Brier scoring per criteria.md.
This is not a going-concern case and is explicitly not argued as one. $810m of cash and securities, a 2028 maturity, positive operating cash flow ($61.1m in H1 2026), no covenant structure on a 1.00% unsecured convertible. The impairment is a valuation and capital-allocation impairment, not a solvency one.
| # | Trigger | Where it would appear | Action |
|---|---|---|---|
| 1 | Organic growth prints below 9% in any quarter | quarterly 8-K exhibit 99.1, organic reconciliation table | Thesis broken — the mean-reversion trade rests on 12–13% organic |
| 2 | FY2026 revenue guidance cut below $813m | Q3 2026 release | Exit |
| 3 | BioLife deal breaks (regulatory block or stockholder vote fails) | 8-K | Re-underwrite: standalone target rises to $176 but the growth mix worsens |
| 4 | Purchase price raised or consideration shifted materially to cash | 8-K / S-4 amendment | Re-underwrite the dilution and the balance sheet |
| 5 | Adjusted-to-GAAP gap widens further — new add-back category beyond "transformation costs" | reconciliation tables | Accounting-quality escalation |
| 5b | ICFR still not effective at 2026-12-31, or a new material weakness, or any further restatement | FY2026 10-K Item 9A (late Feb 2027) | Accounting-quality escalation. A third consecutive year of ineffective ICFR while integrating a $1.5bn acquisition would be disqualifying on its own |
| 6 | Multiple exceeds 13.10x EV/Sales (post-destocking p75) | daily | Target reached; the mean-reversion trade is complete |
| 7 | Converts called on/after 2026-12-18 without a refinancing plan | 8-K | Liquidity re-examination against the $540m BioLife cash outflow |
| Quality Criteria (BINDING) | FAIL — ICFR not effective at 2025-12-31 (inventory-valuation and IT-general-control weaknesses unremediated, after a 2024 revenue restatement); op-margin change +4.1pp organic-adjusted vs ~5pp separation; ROIC 2.7% vs WACC ~10% |
| Valuation Criteria (BINDING) | FAIL — required 27.4% vs demonstrated 3.3% / guided 12%; margin −24.1pp / −15.4pp |
| Liquidity Criteria (BINDING) | equity PASS · options FAIL (max chain OI 15 contracts) |
| Downside Criteria (MEASURED) | $100, −31%, p=27%, named cause: restocking mistaken for demand, unverifiable because the order disclosure was retired |
| Momentum Criteria (MEASURED) | +9.0% 12-1 |
| Consensus Criteria (MEASURED) | INDETERMINATE — quota exhausted, blocks nothing |
| 12-month target | $163 pro forma (+12.3%) / $176 standalone (+21.1%) |
| Vehicle | Common stock only |
| Sizing input | 46.5% realised vol → inverse-vol slot, ≤⅓ size |
The honest summary of this name: a genuinely improving, genuinely organic 12–13% grower whose multiple sits at the 14.5th percentile of its own history — and which is priced for 27% compounding it has never demonstrated, does not guide to, and has no named mechanism to reach. The screen said PASS by +17.6pp. On corrected inputs it is FAIL by 15–24pp. The 12-month setup is nevertheless the most attractive part of this name and is the reason the memo is not a dismissal.
The one thing that would change the analysis fastest is not a valuation input. It is Repligen reinstating a quantified order metric and reporting effective internal control at 2026-12-31. Those two disclosures would convert the memo's two largest unverifiables — is the recovery demand or restocking, and can the reported margin expansion be relied upon — into evidence. Neither is a forecast; both are scheduled disclosures.